AKT2 and hematopoietic and lymphoid system neoplasm: Notably, AKT2 and microRNA-4716–3p expression levels varied across demographic and clinical factors including age, gender, residence, addiction, familial history, treatment, and smoking status (Table 2; Fig. S1; Fig. S2), suggesting their promise as a marker for assessing blood cancer risk.